EP3687537A4 - Neue usp7-inhibitoren zur behandlung eines multiplen myeloms - Google Patents

Neue usp7-inhibitoren zur behandlung eines multiplen myeloms Download PDF

Info

Publication number
EP3687537A4
EP3687537A4 EP18862773.1A EP18862773A EP3687537A4 EP 3687537 A4 EP3687537 A4 EP 3687537A4 EP 18862773 A EP18862773 A EP 18862773A EP 3687537 A4 EP3687537 A4 EP 3687537A4
Authority
EP
European Patent Office
Prior art keywords
novel
multiple myeloma
treating multiple
usp7 inhibitors
usp7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18862773.1A
Other languages
English (en)
French (fr)
Other versions
EP3687537A1 (de
Inventor
Sara BUHRLAGE
Kenneth C. Anderson
Dharminder Chauhan
Sirano DHE-PAGANON
Xiaoxi Liu
Hyuk-Soo SEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP3687537A1 publication Critical patent/EP3687537A1/de
Publication of EP3687537A4 publication Critical patent/EP3687537A4/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP18862773.1A 2017-09-26 2018-09-26 Neue usp7-inhibitoren zur behandlung eines multiplen myeloms Pending EP3687537A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563375P 2017-09-26 2017-09-26
PCT/US2018/052797 WO2019067503A1 (en) 2017-09-26 2018-09-26 NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA

Publications (2)

Publication Number Publication Date
EP3687537A1 EP3687537A1 (de) 2020-08-05
EP3687537A4 true EP3687537A4 (de) 2021-06-16

Family

ID=65903565

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18862773.1A Pending EP3687537A4 (de) 2017-09-26 2018-09-26 Neue usp7-inhibitoren zur behandlung eines multiplen myeloms

Country Status (6)

Country Link
US (2) US11465983B2 (de)
EP (1) EP3687537A4 (de)
JP (2) JP7402792B2 (de)
AU (1) AU2018342089A1 (de)
CA (1) CA3072353A1 (de)
WO (1) WO2019067503A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067503A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2020086595A1 (en) * 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition
EP4110393A1 (de) 2020-02-28 2023-01-04 Immunologik GmbH Inhibitoren von menschlichen deubiquitinasen zur behandlung von coronavirusinfektionen
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053924A1 (fr) * 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Agent analgesique
WO2007147217A1 (en) * 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
EP2565186A1 (de) * 2011-09-02 2013-03-06 Hybrigenics S.A. Spezifische und reversible Inhibitoren von ubiquitinspezifischer Protease 7
WO2016126926A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007272B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н. В. Новые ингибиторы гистондеацетилазы
US9932351B2 (en) * 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
WO2016126935A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
GB201612938D0 (en) 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
WO2019067503A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
WO2020086595A1 (en) 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053924A1 (fr) * 1998-04-17 1999-10-28 Kyowa Hakko Kogyo Co., Ltd. Agent analgesique
WO2007147217A1 (en) * 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
EP2565186A1 (de) * 2011-09-02 2013-03-06 Hybrigenics S.A. Spezifische und reversible Inhibitoren von ubiquitinspezifischer Protease 7
WO2013030218A1 (en) * 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7
WO2016126926A1 (en) * 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAMBERTO ILARIA ET AL: "Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7", CELL CHEMICAL BIOLOGY, vol. 24, no. 12, 21 December 2017 (2017-12-21), pages 1490, XP085326765, ISSN: 2451-9456, DOI: 10.1016/J.CHEMBIOL.2017.09.003 *

Also Published As

Publication number Publication date
US11465983B2 (en) 2022-10-11
JP7402792B2 (ja) 2023-12-21
WO2019067503A1 (en) 2019-04-04
EP3687537A1 (de) 2020-08-05
AU2018342089A1 (en) 2020-02-27
JP2023164918A (ja) 2023-11-14
JP2020535124A (ja) 2020-12-03
US20230265070A1 (en) 2023-08-24
US20200347031A1 (en) 2020-11-05
CA3072353A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
IL292642A (en) ras inhibitors
IL282535A (en) Transmuted 6-azabanzimidazole compounds as hpk1 inhibitors
EP3307713A4 (de) Ezh2-hemmer zur behandlung von lymphomen
EP3833355A4 (de) Prmt5-inhibitoren
EP3687537A4 (de) Neue usp7-inhibitoren zur behandlung eines multiplen myeloms
EP3801503A4 (de) Inhibitoren von sarm1
EP3706747A4 (de) Prmt5-inhibitoren
EP3906029A4 (de) Inhibitoren der menin-mll-interaktion
EP3307068A4 (de) Mct4-inhibitoren zu behandlung von erkrankungen
EP3817736A4 (de) Pikfyve-inhibitoren
EP3833669A4 (de) Prmt5-inhibitoren
EP3316887A4 (de) Gls1-hemmer zu behandlung von erkrankungen
EP3833668A4 (de) Prmt5-inhibitoren
EP3334432A4 (de) Cerdulatinib zur behandlung von myelom
EP3706742A4 (de) Prmt5-inhibitoren
EP3720495A4 (de) Heterocyclische verbindungen als prmt5-inhibitoren
EP3600301A4 (de) Kdm4-inhibitoren
IL276013A (en) pi4kiiibeta inhibitors
EP3519429A4 (de) Bakterielle inhibitoren
EP3801499A4 (de) Inhibitoren von sarm1
EP3801500A4 (de) Inhibitoren von sarm1
EP3768384A4 (de) Verfahren zur behandlung von melanomen
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
EP3976797A4 (de) Anti-crispr-inhibitoren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/06 20060101ALI20210223BHEP

Ipc: C07D 403/06 20060101ALI20210223BHEP

Ipc: A61K 31/44 20060101ALI20210223BHEP

Ipc: A61K 31/4436 20060101ALI20210223BHEP

Ipc: C07D 401/14 20060101AFI20210223BHEP

Ipc: A61K 31/4439 20060101ALI20210223BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031440000

Ipc: C07D0401140000

A4 Supplementary search report drawn up and despatched

Effective date: 20210519

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/14 20060101AFI20210512BHEP

Ipc: C07D 403/06 20060101ALI20210512BHEP

Ipc: C07D 401/06 20060101ALI20210512BHEP

Ipc: A61K 31/44 20060101ALI20210512BHEP

Ipc: A61K 31/4436 20060101ALI20210512BHEP

Ipc: A61K 31/4439 20060101ALI20210512BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524